Motivation: Genotype-phenotype modeling problems are often overcomplete, or ill-posed, since the number of potential predictors -genes, proteins, mutations and their interactions -is large relative to the number of measured outcomes. Such data sets can still be used to train sparse parameter models that generalize accurately, by exerting a principle similar to Occam's Razor: When many possible theories can explain the observations, the most simple is most likely to be correct. We apply this philosophy to modeling the drug response of Type-1 Human Immunodeficiency Virus (HIV-1). Due to the decreasing expense of genetic sequencing relative to in vitro phenotype testing, a statistical model that reliably predicts viral drug response from genetic data is an important tool in the selection of antiretroviral therapy (ART). The optimization techniques described will have application to many genotype-phenotype modeling problems for the purpose of enhancing clinical decisions. Results: We describe two regression techniques for predicting viral phenotype in response to ART from genetic sequence data. Both techniques employ convex optimization for the continuous subset selection of a sparse set of model parameters. The first technique, the Least Absolute Shrinkage and Selection Operator (LASSO), uses the l 1 norm loss function to create a sparse linear model; the second, the Support Vector Machine (SVM) with radial basis kernel functions, uses the -insensitive loss function to create a sparse nonlinear model. The techniques are applied to predicting the response of the HIV-1 virus to ten Reverse Transcriptase Inhibitor (RTI) and seven Protease Inhibitor (PI) drugs. The genetic data is derived from the HIV coding sequences for the reverse transcriptase and protease enzymes. When tested by cross-validation with actual laboratory measurements, these models predict drug response phenotype more accurately than models previously discussed in the literature, and other canonical techniques described here. Key features of the methods that enable this performance are the tendency to generate simple models where many of the parameters are zero, and the convexity of the cost function, which assures that we can find model parameters to globally minimize the cost function for a particular training data set.
Introduction
As of today, approved ART drugs consist of a list of eleven RTIs: seven nucleoside, one nucleotide and three non-nucleoside; seven PIs; and one fusion/entry inhibitor. (Carpenter, C. C. et al., 2000; WHO 2003) Given the current rollout of ART drugs around the world (UNAIDS 2004) , the appearance of resistance strains of the virus is inevitable, both due to the low genetic barrier to resistance (D'Aquila, R. Fessel, W. J. et al., 2003; Kuritzkes, D. R. et al., 1996; Molla, A. et al., 1996; Rhee, S. Y. et al., 2003; Shafer, R. W. 2004; Zolopa, A. R. et al., 1999) and to poor drug adherence. (Sherr, L. 2000) Consequently, techniques to predict how mutated viruses will respond to anti-retroviral therapy are increasingly important as they will influence the outcome for salvage therapies. The rapidly decreasing cost of viral genetic sequencing -with volume pricing as low as $5 for pre-prepared sequences (Macrogen) -makes the selection of drugs based on viral genetic sequence data an attractive option than the more costly and technically involved in vitro phenotype measurement. (Meynard, J. L. et al., 2002; Shafer, R. W. 2002) The use of sequence data, however, necessitates accurate predictions of viral drug response based on the appearance of viral genetic mutations. The many different combinations of viral mutations make it difficult to design a model that includes all the genetic cofactors and their interactions, and to train the model with limited data. (Kijak, G. H. et al., 2003; Ravela, J. et al., 2003) The latter problem is exacerbated in the context of modeling in vivo drug response, (De Luca, A. et al., 2003) where the many different combinations of drug regimens make it difficult to collect sufficiently large data sets for any particular regimen that contains the necessary variables, namely baseline clinical status, treatment history, clinical outcome and genetic sequence. We focus here on the in vitro scenario, but the techniques discussed are also applicable to the more complex in vivo scenario 1 . Resistance to antiviral drugs can be the result of one mutation within the RT or protease sequences, or the combination of multiple mutations. (DHHS 2004) The RT enzyme is coded by a key set of 560 codons; the protease enzyme by 99 codons. By considering only mutations that alter the amino acids, each amino acid locus has 19 possible mutations, so there are a total of 10,640 possible mutations that differ from wild type on the RT enzyme, and 1,981 possible mutations on the protease enzyme. Using a simple linear model, where each mutation encountered in the data (not all mutations will occur) is associated with a particular weighting, or linear regression parameter, we may have several thousand parameters. If only several hundred patient samples are available for each drug, the problem is overcomplete, or ill-posed in the Hadamard sense, (Hadamard, J. 1923 ) since we have more parameters to estimate than independent equations. Many techniques exist that can be applied to the problem of constructing models for the ill-posed problem. These include combining a priori expert knowledge with observations to create expert-rule based systems, (ANRS 2004; HIVDB 2004) as well as statistical methods including i) ridge regression, (Daniels, M. J. et al., 2001; Neter, J. et al., 1990) ii) principal component analysis, (Jolliffe, I. T. 2002; Mardia, K. V. 1980) iii) decision trees, (Breiman, L. 1984; Hastie, T. J., Tibshirani, R.J. 1996) iv) stepwise selection techniques, (Ryan, T. P. 1996; Wang, K. et al., 2004) v) neural networks, (Draghici, S. et al., 2003; Wang, D. et al., 2003) vi) linear support vector machines, Vapnik, V. N. 1998) vii) the Least Absolute Shrinkage and Selection Operator (LASSO), (Efron, B. et al., 2003; Tibshirani, R. 1996) and viii) non-linear Support Vector Machines (SVM). (Schölkopf, B., Burges, C., Smola, A. 1999; Vapnik, V. N. 1998) We compare these techniques, and focus in particular on the latter two, which have been used to generate results superior to those of recently published approaches. DiRienzo, A. G. et al., 2003; Kijak, G. H. et al., 2003; Wang, K. et al., 2004) We explain why the LASSO and the SVM techniques, both of which generate convex cost functions and sparse parameter sets, achieve superior performance.
Three main industry-standard expert systems are typically used to predict the susceptibility of HIV viruses to ART drugs: the ANRS-AC11 System (ANRS 2004), the Rega System (Rega 2004) , and the Stanford HIVdb System. It is commonplace in the literature for new algorithms to be benchmarked against these expert systems. None of these expert systems, however, is designed to perform direct prediction of phenotypic response, but rather to provide a numeric score by which different drugs can be compared, or to classify the drugs into discrete groupings such as Sensitive, Intermediate and Resistant. (HIVDB 2004) In addition, it has been clearly established (De Luca, A. e. a. 2004; Wang, K. et al., 2004) that statistical algorithms, such as linear regression models trained with stepwise selection, substantially outperform expert systems in prediction of phenotypic outcome. Consequently, we will only compare a set of statistical techniques which include the best performing methods recently disclosed in the literature.
Methods

Source of the DataSet
We used the Stanford HIV RT and Protease drug resistance database to train and test our models. (HIVDB 2004) This data consists of several thousand in vitro phenotypic tests of HIV-1 viruses for which the Protease and/or RT encoding segments have been sequenced. Tests have been performed on ten RTI drugs and seven PI drugs. The RTIs include lamivudine (3TC), abacavir (ABC), zidovudine (AZT), stavudine (D4T), zalcitabine (DDC), didanosine (DDI), delaviradine (DLV), efavirenz (EFV), nevirapine (NVP) and tenofovir (TDF). The PIs include ampranavir (APV), atazanavir (ATV), nelfinavir (NFV), ritonavir (RTV), saquinavir (SQV), lopinavir (LPV) and indinavir (IDV)). The in vitro drug susceptibility methods used to gather the phenotypic data was ViroLogic TM . (Virologic 2005 ) Details of the approach to gathering and rendering the data are provided by Robert Shafer's group at the site http://hivdb.stanford.edu. We will only discuss those issues directly relevant to formulating the statistical problem.
Problem Formulation
For each drug, we structure the data into pairs of the form N i y
where N is the number of samples constituting the training data, i y is the measured drug fold resistance, and i x is the vector of mutations plus a constant term,
of possible mutations on the relevant enzyme. We set element x im =1 if the m th mutation is present on i th sample, and set x im =0 otherwise. Each mutation is characterized both by the codon locus and the substituted amino acid. Mutations that do not affect the amino acid sequence are ignored. Note that only mutations present in more than 1% percent of the samples for each drug are included in the set of possible predictors for a model, since it is improbable that mutations associated with resistance would occur so infrequently. The measurement y i represents the fold resistance of the drug for the mutated virus as compared to the wild type. Specifically, y i is the log of the ratio of the IC 50 (the concentration of the drug required to slow down replication by 50%) of the mutated virus, as compared to the IC 50 of the wild type virus. Our goal is to develop a model for each drug that accurately predicts y i from x i . In order to perform batch optimization on the data, we stack the independent variables in an N by M+1 matrix, 
Where vector ŷ is the prediction of phenotypes y , y denotes the mean of the elements in vector y and 1 r denotes the vector of all ones. For each drug and each method, the data is randomly subdivided in the ratio 9:1 for training and testing, respectively. Ten different subdivisions are performed in order to generate the vector ŷ and R without any overlap of training and testing data. This entire process is then repeated ten times to generate ten different values of R. The ten different values of R are averaged to generate the R reported. We also determine the standard deviation of R for each of the models measured over the ten different experiments to ensure that we are comparing models in a statistically significant manner. Table 1 displays the results of the above mentioned models for the seven PI drugs; Table 2 displays the results for the ten RTI drugs. Results are displayed in terms of correlation coefficient R, averaged over ten subdivisions of the training and test data as described above. The estimated standard deviation of the mean value of R, computed from the sample variance, is also displayed. The number of available samples for each drug is shown in the last row. The methods tested, in order of increasing average performance, are: i) RR -Ridge Regression, ii) DT -Decision Trees, iii) NN -Neural Networks, iv) PCA -Principal Component Analysis, v) SS -Stepwise Selection, vi) SVM_L -Support Vector Machines with Linear Kernels Vapnik, V. N. 1998) , vii) LASSO -Least Absolute Shrinkage and Selection Operator, and viii) SVM -Support Vector Machines with Radial Basis Kernels (Schölkopf, B., Burges, C., Smola, A. 1999; Vapnik, V. N. 1998) . The information in the last columns of Table 1 and Table 2 is depicted in Figure 1 . The circles display the correlation coefficient R averaged over ten different experiments for each PI, and then averaged over the seven different PIs. The diamonds display the correlation coefficient R averaged over ten different experiments for each RTI, and then averaged over the ten different RTIs. The one standard deviation error bars are also indicated. Wherever modeling techniques involve tuning parameters, these have been adjusted for optimal performance using a grid search approach: each point in the grid is associated with a quantized set of tuning parameter, and that point of the grid that produces the best correlation coefficient R in cross-validation is selected. Once the best-performing tuning parameters are selected, the model is re-trained and tested to generate a new correlation coefficient. In all cases, the grid quantization was fine enough that the difference in the prediction resulting from adjacent grid points lay below the experimental noise floor.
Results
Although there are strong trends in the data, it should be noted that due to differences in the number of samples, interactions of the underlying genetic predictors, and other idiosyncrasies in the data that vary between drugs, the R achieved by each algorithm varies from drug to drug. This can be seen by studying the individual drug columns of Table 1 and Table 2 Table 2 : Correlation coefficient (R in %) of measured and predicted response to RTI drugs, averaged over ten different 9:1 splits of training and testing data. The standard deviation (Std. dev.) of the results is shown in gray; the number of measured drug responses is shown in the last row (Samples) Figure 1 : Correlation Coefficient R of measured and predicted response, averaged over ten different 9:1 splits of training and testing data, and then averaged over seven PIs or ten RTIs respectively.
Of all the methods, SVM performs best, slightly outperforming LASSO (P<0.001 for the RTIs; P=0.18 for the PIs) 2 . The performance of SVM trained with the -insensitive loss function is considerably better than that of previously reported methods based on the support vector machine. Wang, D. et al., 2003) . Note that SVM, which uses nonlinear kernel functions, outperforms SVM_L which uses linear kernel functions, and which is also trained using the -insensitive loss function (P = 0.003 for RTIs; P < 0.001 for PIs). The SVM considerably outperforms the other nonlinear technique which uses neural networks (Wang, D. et al., 2003) and which does not create a convex cost function (P<0.001 for both RTIs and PIs). The LASSO technique, which trains a linear regression model using a convex cost function and continuous subset selection, considerably outperforms the SS technique (P<0.001 for both PIs and RTIs). The top five methods, namely SS, PCA, SVM_L, LASSO, SVM_R, all 2 Wherever a P-value is quoted to indicate the difference between methods, it is computed as follows. Let 1 R and 2 R be the sample means of the correlation coefficients for methods 1 and 2, each averaged over 10 different experiments and all different drugs. Since the data is randomly subdivided ten times in the ratio 9:1 for training and testing for each drug and each method, 1 R and 2 R will be independent. Let R S and 2 R S be the estimated standard deviations of the means as shown in the last columns of Table 1 and Table 2 . The test statistic is computed:
. The P-value is computed using the two-tailed test:
Since D has a Student-T distribution with more than 100 degrees of freedom, it can be treated as normally distributed as )
tend to generate models that are sparse, or have a limited number of non-zero parameters. This will be discussed further in the next section. In order to illustrate the subset of mutations selected as predictors, we will focus on the second-best performing model, namely the LASSO, which creates a linear regression model that, unlike SVM, does not attempt to emulate nonlinear or logical coupling between the predictors. Consequently, it is straightforward to show how many predictors are selected. Table 3 shows the number of mutations selected by the LASSO as predictors for each PI drug, together with the number of mutations, and the total number of samples, used in training each model. The same table is shown for the RTI drugs in Table 4 The selected mutations may also enhance understanding of the causes of drug resistance. Figures  2, 3 and 4 show the value of the parameters selected by the LASSO for predicting response to PI, Nucleoside RTIs (NRTIs), and Non-Nucleoside RTIs (NNRTIs), respectively. Each row in the figures represents a drug; each column represents a mutation. Relevant mutations are on the protease enzyme for PI drugs and on the RT enzyme for NRTI and NNRTI drugs. The shading of each square indicates the value of the parameter associated with that mutation for that drug. As indicated by the color-bar on the right, those predictors that are shaded darker are associates with increased resistance; those parameters that are shaded lighter are associated with increased susceptibility. The mutations are ordered from left to right in order of decreasing magnitude of the average of the associated parameter. The associated parameter is averaged over all rows, or drugs, in the class. Only those mutations associated with the forty largest parameter magnitudes are shown. Note that for a particular mutation, or column, the value of the parameter varies considerably over the rows, or the different drugs in the same class. For the algorithms RR, DT, NN, and SS, the model was not trained on all mutations, but rather on a subset of mutations occurring at those loci that have been determined to affect resistance by the Department of Health and Human Services (DHHS 2004; Wang, K. et al., 2004) . The reduction in the number of independent variables was found to improve the performance of these algorithms. In the case of the SVM_L algorithm, best performance for RTIs was achieved using only the DHHS mutation subset, while best performance for PIs was achieved by training the model on all mutations. For all other algorithms, best overall performance was achieved by training the model on all mutations. The set of mutations shown in Figures 2, 3 and 4 that were selected by the LASSO as predictors, but are not associated with loci determined by DHHS to affect resistance, (DHHS 2004; Wang, K. et al., 2004) are: for PIs -19P, 91S, 67F, 4S, 37C, 11I, 14Z; for NRTIs -68G, 203D, 245T, 208Y, 218E, 208H, 35I, 11K, 40F, 281K; and for NNRTIs -139R, 317A, 35M, 102R, 241L, 322T, 379G, 292I, 294T, 211T, 142V. Note that in some cases, such as for the LASSO 3 , the performance for particular drugs, such as LPV, was significantly improved (P<0.001) when all mutations were included in the model (R = 86.78, Std. dev = 0.17) as compared to the case when only those loci recognized to affect resistance by DHHS (DHHS 2004) were included (R = 81.72, Std. dev. = 0.18). This suggests that other mutations, beyond those recognized by the DHHS, play a role in resistance to such drugs, and the topic warrants further study 4 .
Discussion
Motivation for the LASSO and the l 1 Selection Function 3 A similar effect was also observed with the SVM. 4 As a first step, this tendency should be verified with a new data set.
We describe here the explicit use of the l 1 norm in the LASSO (Efron, B. et al., 2003; Tibshirani, R. 1996) , and we extend this discussion to the SVM trained with the -insensitive loss function in the next section. We begin by discussing the significance of sparse models.
When the number of predictors M exceeds the number of training samples N, the modeling problem is overcomplete, or ill-posed (Hadamard, J. 1923) , since any arbitrary subset of N predictors is sufficient to yield a linear model with zero error on the training data, so long as the associated columns in the X matrix are linearly independent. Consequently, one is disinclined to put faith in an N-predictor model returned by a linear regression method. Suppose, however, a model with significantly fewer than N variables has low training error. The more sparse the model, the less probable that low training error could be a chance artifact; hence, the more likely that the predictors are causally related to the dependent variable. This underlies the importance of sparse solutions in overcomplete problems, as is the case for the RTI data. A similar argument can be applied to ill-conditioned problems characterized by a large condition number on the matrix X T X. This is the case for several PI drugs for which N>M. The problem is ill-conditioned due to co-linearity between the predictors resulting from similar genealogy of the sequences. In such a case, the estimated parameters b are highly susceptible to the model error, as well as to measurement noise, and as a result, the estimator has high variance and is unlikely to generalize accurately. Overcomplete and ill-conditioned problems are typical of genetic data, where the number of possible predictors-genes, proteins, or, in our case, mutation sites-is large relative to the number of measured outcomes.
One canonical approach to such cases is best subset selection (Hastie, T. et al., 2001 ). This involves selecting a maximum number of predictors to be used, M' N, and cross-validating the models that are generated from all possible subsets of M' or fewer predictors. When M=M', this involves 2 M different subsets. Using advanced computational techniques, (Hastie, T. et al., 2001 ) the problem may be solved for M 50. However, this approach is intractable for the number of potential predictors -and the number of predictors selected -in the results above. A computationally tractable approach is stepwise selection (Neter, J. et al., 1990) , which adds a single predictor to the model at each step, based on that variable having the highest F-test statistic indicating the level of significance with which it is correlated with prediction error. After each variable is added, the remaining variables are all checked to ensure that none of them have dropped below a threshold of statistical significance in their association with the prediction error of the model. This technique has been successfully applied to the problem of drug response prediction. (Wang, K. et al., 2004) However, due to the discrete nature of the selection process, small changes in the data can considerably alter the chosen set of predictors. The presence or absence of one variable will affect the statistical significance associated with another variable and whether that variable is included or rejected from the model. This affects accuracy in generalization, particularly for ill-conditioned problems.
Another approach is for the values of the estimated parameters b to be constrained by means of a shrinkage function. Shrinkage functions tend to add bias to the estimator but reduce the estimator's variance (Hastie, T. et al., 2001) and hence improve the ability to generalize from ill-conditioned data. A canonical shrinkage function is the square of the l 2 norm, or the sum of the squares of the parameters, and this is applied in ridge regression which finds the parameters according to: where is a tuning parameter, typically determined by cross-validation. This method is nonsparse and does not set parameters to 0. This tends to undermine accuracy in generalization, and makes solutions difficult to interpret. These problems are addressed by the LASSO technique. In contrast to stepwise selection, the LASSO does not perform discrete acceptance or rejection of predictor variables; rather it allows one to select en-masse, via a continuous subset optimization, the set of variables that together are the most effective predictors. It uses the l 1 norm shrinkage function:
where is typically set by cross-validation in order to estimate the optimal tradeoff between bias and variance in the estimator. The LASSO will tend to generate sparse models by setting many of the parameters to 0. , and the x-axis and y-axis represent the two parameters b 1 and b 2 , respectively. Compare the use of the l 1 and l 2 shrinkage functions, where in both cases we find a solution that fits the training data equally well such that ||y-Xb|| 2 =2. The large circle, small circle, and square respectively represent level curves for the cost functions ||y-Xb|| 2 , the l 2 norm ||b|| 2 , and the l 1 norm |b| 1 =|b 1 |+|b 2 |. A solution for ridge regression (l 2 norm) is found where the two circles meet; a solution for the LASSO (l 1 norm) is found where the square and the large circle intersect. Due to the "pointiness" of the level cure for the l 1 norm, we have found a solution that lies on the axis b 1 and is therefore sparse. This argument, extended into higher dimensions, explains the tendency of LASSO to produce sparse solutions, and suggests why the results achieved are measurably better than those of techniques reported in the literature Beerenwinkel, N. et al., 2002; Draghici, S. et al., 2003; Wang, D. et al., 2003; Wang, K. et al., 2004) .
The l 1 norm can be viewed as the most selective shrinkage function that remains convex. Since a convex function has a global minimum and no local minima, convexity guarantees that we can find the one global solution for a given data set. (Boyd S., V., L. 2004; Murray, W., Gill, P. and Wright, M. 1981) A highly efficient recent algorithm, termed Least Angle Regression, (Efron, B. et al., 2003; Osborne, M. R. et al., 2000) is guaranteed to converge to the global solution of the LASSO in M steps. Code for solving the LASSO, for many hundreds or thousands of potential predictors, is available in MATLAB via anonymous ftp at ftp://ftp.genesecurity.net/code/LASSO. 
Support Vector Machines, Convexity and Sparsity
In a modeling problem where there is coupling between the independent variables, or other nonlinear effects, the performance of a linear regression model as used by the LASSO will be suboptimal. One approach to modeling nonlinear effects in ART drug response prediction is to use neural networks. (Draghici, S. et al., 2003; Wang, D. et al., 2003) . In the results above, we focused on the techniques of Wang since these were reported to achieve the better performance of the two neural network methods, and are better suited to the regression problem that we address. In general, there are two key challenges with neural network approaches. The first is that the cost function to be minimized is non-convex, so that it is extremely difficult to converge in training to the global minimum that generates optimal parameter values, particularly when there are a large number of predictors as in our case. The second is that the complex neural network models tend to be non-sparse, and consequently do not generalize well. This problem is addressed in two ways (Wang, D. et al., 2003) for the NN algorithm described above: Firstly, using cross validation, the network training parameters and the number of hidden layer nodes that generalized most accurately for each drug are determined. Secondly, for each prediction, ten independent neural networks are trained and then all ten predictions are averaged to create a single model prediction. These techniques (Wang, D. et al., 2003) are at best palliative and do not address the fundamental challenges of the non-sparse, non-convex, neural network approach.
As the results show, a preferable technique for creating nonlinear models is the use of SVMs which are trained with convex cost functions, and which tend to produce sparse models that generalize well. SVMs are learning algorithms that can perform real-valued function approximation and can achieve accurate generalization of sample data even when the estimation problem is ill-posed in the Hadamard sense (Hadamard, J. 1923; Vapnik, V. N. 1998) . The ability of SVMs to accurately generalize is influenced by two selectable features in the SVM model and training algorithm. The first is the selection of the cost function, or the function that we seek to minimize in training. The second is the selection of the kernels of the SVM, or those functions that enable the SVM to map complex nonlinear functions, involving interactions between the independent variables, using a relatively small set of linear regression parameters (Burges, C. J. 1998; Vapnik, V. N. 1998) . We discuss these features below.
Consider modeling i y with a linear function approximation:
. Suppose we seek to estimate b by minimizing a cost function consisting of a l 2 shrinkage function on the parameters, together with the " -insensitive loss" function, which does not penalize data fitting errors below some >0. This SV regression may be formulated as: (Vapnik, V. N. 1998) ( )
subject to the constraints:
The second term of the cost function minimizes the absolute value of the modeling errors, beyond the insensitivity threshold . Parameter C allows one to scale the relative importance of the error vs. the shrinkage on the weights. Since the regression model is linear and the -insensitive loss function is convex, the above constrained optimization is convex, and can consequently be solved by finding the saddlepoint of a Lagrangian, in order to satisfy the Karush-Kuhn-Tucker (KKT) conditions. (Boyd S., V., L. 2004) . In Appendix I, by referring to the Lagrangian dual problem, we describe how the use of the -insensitive loss function in combination with an l 2 shrinkage on the parameters is similar to the explicit use of an l 1 shrinkage on the parameters, in terms of the tendency to generate sparse models.
Also in Appendix I, we describe how convexity is extended to the nonlinear case with the use of kernel functions in the regression model
Where K(x,x 0 )=1 by definition. The kernel function K may be any continuous symmetric function that satisfies the Mercer Condition (Vapnik, V. N. 1998) , which implies that it has an expansion of the form:
Here, z k (x) represents the k th element of a higher-dimensional vector z(x) in feature space to which the input vector x can be mapped. While an SVM kernel may be nonlinear with respect to the vector x in input space, it will be linear with respect to the vector z(x) in feature space (Vapnik, V. N. 1998) . The radial basis kernel function used to generate our results has the form K(x,x i )=exp (-|x-x i |) , where is determined by cross validation, as described above. The code to implement the SVM with the -insensitive loss function and various kernel functions is available via anonymous ftp at ftp://ftp.genesecurity.net/code/SVM.
Conclusions
We have described the use of convex optimization techniques to achieve continuous subset selection of sparse parameter sets in order to train drug-response prediction models that generalize accurately. We have described the use of the LASSO which applies the l 1 norm shrinkage function to generate a sparse set of linear regression parameters. We have also described the use of the SVM with radial basis kernel functions and trained with the -insensitive loss function to generate sparse nonlinear models. Both the LASSO and the nonlinear SVM techniques are able to model the response of mutated viruses to anti-retroviral drugs more accurately, as measured by cross-validation, than any of the techniques previously published. The superior performance of these techniques is explained in terms of the convexity of their cost functions used in training, and their tendency to produce sparse models. Convexity assures that one can find the globally optimal parameters for a particular training data set when there are many potential predictors. Sparse models tend to generalize well, particularly in the context of underdetermined or ill-conditioned data, as is typical of genetic data. The l 1 norm may be viewed as the most selective convex function. The SVM, which uses an l 2 shrinkage function together with an -insensitive loss function, tends to produce an effect similar to the explicit use of the l 1 norm as a shrinkage function applied to the parameters associated with the support vectors.
Two advantages of LASSO are that the resulting model is easy to interpret since the parameters directly combine predictors, or expressions involving predictors, rather than support vectors; and that the LASSO can be efficiently trained for models involving many potential predictors using the LARS algorithm. The performance of the LASSO may be enhanced by adding nonlinear or logical combinations of predictors to the model. Logical combinations can be derived from those generated by a decision tree, from logical expressions described by expert rules, from the technique of logic regression, (Kooperberg, C. et al., 2001) or even from a set of random permutations of logical terms.
Note that other techniques exist that use shrinkage function more selective than the l 1 norm. For example, log-shrinkage regression (Fazel, M. 2002; Singer, J. 2004 ) uses a shrinkage function derived from coding theory which measures the amount of information residing in the model parameter set. While offering a theoretically intriguing approach for seeking a sparse set of parameters, the non-convexity of the resulting cost function means that solving the logshrinkage regression is computationally challenging, and for large sets of predictors will yield only a local, rather than a global, minimum for the given data.
Appendix I
The Lagrangian for the cost and constraints described in Equations (4)- (7) is: 
subject to:
This enables us to compute the vector b and fully define the SVM model for the -insensitive loss function. Note from Equation (12) 
The resulting model will tend to be sparse in that many of the parameters in the set { i ,i=1…M} will be 0, corresponding to those pairs (x i, y i ) that lie within the insensitive error bound . . vectors x i corresponding to non-zero values i are known as the support vectors. The number of support vectors depends on the value of the tunable parameter C, the training data, and the suitability of the model. We now describe how the model can be augmented to accommodate complex nonlinear functions with the use of kernel functions. We then show that the -insensitive loss function is related to the l 1 norm shrinkage function, and essentially achieves the same thing, namely the en-masse selection of a sparse parameter set.
In order to model nonlinear functions, the inner product of Equation (16) is replaced with a kernel function that computes a more complex interaction between the vectors, as described by Equation (8). Since the model remains linear in the parameters i , we can use exactly the same convex optimization methods described above, and replace all terms 
subject to the same constraints as Equations (14) and (15) above. Now, we illustrate the implicit use of the l 1 norm on the parameters i . Consider that instead of trying to optimize the expression in Equation (17) (Vapnik, V. N. 1998) 6 Using the fact that the kernel functions satisfy Mercer's condition (Vapnik, V. N. 1998) , it can be shown that the Lagrangian dual problem may be described as maximizing 
subject to the constraints 0 ,
This dual problem will coincide with that of the -insensitive loss function if f(x) is sufficiently smooth and there is no noise in its measurement. In that case, y i =f(x i ) and the value C for the SV method can be chosen sufficiently large such that the constraints C i i + , 0 can simply become the constraints in Equation (20) . Under these conditions, we see that sparse function approximation is achieved, similar to effect of the explicit use of the l 1 shrinkage function. 6 Note that the requirement i + i -=0, i=1…N is already implicit in the optimization of Equation (20) since the constraints (5) and (6) cannot be simultaneously active, so one of the Lagrange multipliers + i or i must be 0.
